WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 1-Jun.-2018 (data as of 25-May-2018)
Next overall update Mid-July 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 5'2101 Infant (under 12 months) mortality rate: 322
GDP / capita (US$): 10'4141 Child (under 5 years) mortality rate: 452

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 2'534  2'480  2'426  2'371  2'317  1'899  1'415  1'013 
Births 73  72  72  71  70  60  54  43 
Surviving infants 70  70  69  68  67  56  50  40 
Pop. less than 5 years 349  344  335  327  318  277  234  188 
Pop. less than 15 years 930  915  898  883  868  769  618  473 
Female 15-49 years 674  660  645  630  615  484  339  221 

Number of reported cases

(Click for retrospective incidence data for Namibia)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  16  40  212  477  1'028  469 
Mumps
ChartChart
 
Pertussis
ChartChart
  30 
Polio*
ChartChart
 
Rubella
ChartChart
  29  37  625  357  40 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  10 
Tetanus (total)**
ChartChart
  148  19 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Namibia)
Vaccine year result method % card seen                                                
BCG 2012  94  DHS   70  94  94  94  97  94  77  88 
DTP1 2012  93  DHS   70  98  98  98  92  94  90 
DTP3 2012  84  DHS   70  92  92  92  88  89  79  59 
DTP4          55 
IPV1          46  46 
HepB_BD          87  87  87 
HepB3 2012  84  DHS   70  92  92  92  88  89 
Hib3 2012  84  DHS   70  92  92  92  88  89 
JapEnc         
MCV1          85  85  85  83  82  69  57 
MCV2          32 
MenA         
PCV1          73  88  89  61 
PCV2          70  86  89 
PCV3          81  81  81 
Pol3 2012  74  DHS   70  92  92  92  88  89  80  59 
Rota1          86  87  91  61 
RotaC          86  86  87 
RCV1          85 
TT2plus 2012  36  DHS   70  66  70  71  72  60  50 
PAB          75  78  85 
VAD1          99*  75  83  82 
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Namibia)
BCG
ChartChart
  94  94  97  94  77 
DTP1
ChartChart
  98  98  92  94  90 
DTP3
ChartChart
  92  92  88  89  79 
HepB3
ChartChart
  92  92  88  89 
HepB_BD
ChartChart
  87  87 
Hib3
ChartChart
  92  92  88  89 
IPV1
 
MCV1
ChartChart
  85  85  83  82  69 
MCV2
ChartChart
 
PCV3
ChartChart
  81  81 
Pol3
ChartChart
  92  92  88  89  80 
RCV1
ChartChart
 
RotaC
ChartChart
  87  87 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 34  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 47
From 80 to 89% 47
From 50 to 79% 6
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
bOPV 6, 10 years; No
DT 5,10 years; Yes +subnational school healh program (1st dose Y6, 2nd dose Y10)
DTwPHibHepB 6, 10, 14 weeks; Yes
HepB_Pediatric birth; Yes
IPV 14 weeks; Yes
Measles 9 months; No
MR 9, 15 months
OPV Birth; 6, 10, 14 weeks; Yes
Pneumo_conj 6, 10, 14 weeks; Yes
Rotavirus 6, 10 weeks; Yes
TT 15 years; +4, +6 weeks; +1, +1 years; Yes CBAW
VitaminA 6, 12, 18, 26, 33, 39 months; Yes

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2018-2022  2016-2020  2016 - 2020  2011-2015  2011-2015  2011 - 2015  2011 - 2015 
Nº of districts with microplans that include activities to raise immunization coverage number 34  34     

System performance

Total Nº districts in country number 34  34  34  34  35  34  34 
Nº districts with DTP3 coverage >=80% number 32  27  33  25  31  23  23 
% of districts with DTP3 coverage >=80% From 0 to 100% 94  79  97  74  89  68  68 
Nº districts with measles (MCV1) coverage >=95% number
% of districts with MCV1 coverage >=95% From 0 to 100% 21  15  15  20  12 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  No  No  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  No  Yes  Yes  No 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 100  94          100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No  No  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2018
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.